Jim Kramer here to share with you a sample of my take on the market from today's

CNBC Investing Club warning meeting.

Jeff, I had to come back and share with club members some things that I learned that

are kind of off the table that people didn't get that I can help club members for because

they deserve special stuff.

So I came back.

Well, we're glad to have you back.

Why don't we just jump right into it?

Sure.

You're fresh off the JPMorgan Healthcare Conference.

You sat down with several clubs CEOs, Bristol Myers, Lilly, Abbott Labs.

Yes.

Now, Bristol Myers dramatically undervalued happened to come and talk with me the same day that

that J&J bought a company that, by the way, does not have the solution to schizophrenia from 2019.

I don't understand the J&J acquisition, but it certainly didn't hurt Bristol Myers. I would buy that aggressively.

The numbers that they get and where they're going with bipolar, where they're going

with Alzheimer's, is going to make it so that may be the best stock we own for 2026.

And so the ad interview was Monday.

You can check it out online if you haven't seen it.

So I guess if it's not mentioned today, we could buy it tomorrow, restricted today. We have to. The numbers that they're getting are, there are no side effects. This drug will be used by even, I was speaking with the mayor of San Francisco. It will be the antidote to homelessness because he said, a huge percentage of

people are schizophrenic. Yeah. And then Lily, you sat down with Rick's maybe five,

10 minutes after they gave their prelim Q4 numbers, which were solved, but the 25 guidance

...